Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CSL300 (clazakizumab) in end stage kidney disease patients on dialysis with ASCVD risk
jRCT2061240044Phase 3Recruiting
- Sponsor
- CSL Limited
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD), atherosclerotic disease and diabetes mellitus (DM) comparing CSL300 (clazakizumab) with Placebo (2 arms). Primary endpoint: Time to first occurrence of cardiovascular death or myocardial infarction. Started Oct 2024; status: recruiting.
02
Drugs
clazakizumab
03
Conditions
chronic kidney disease (CKD)atherosclerotic diseasediabetes mellitus (DM)
Beyond the preview
Go deeper on jRCT2061240044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061240044.